biostudies-literatureUnknown135COVID-19 RISk and Treatments (CORIST) Collaboration<h4>Objective</h4>The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID-19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418) to retrospectively investigate the relationship between RAAS inhibitors and COVID-19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies.<h4>Methods</h4>We analyzed 4069 unselected patients with laboratory-confirmed SARS-CoV-2 infection and hospitalized in 34 clinical centers in Italy from February 19, 2020 to May 23, 2020. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin-receptoVascular pharmacology106805https://www.ebi.ac.uk/biostudies/studies/S-EPMC7521934biostudies-literatureRAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.PMC7521934Aucella FMarotta CCingolani ASignorelli CMenicanti LCianfrone SRossi MLeone AAl Moghazi SSangiovanni VScoppettuolo GMennuni MPinchera BGuarnieri GCascio ADi Castelnuovo AMancarella SPoletti VCaiano LGraziani EScorzolini LSgariglia RColombo CMastroianni FGentile ICostanzo SAgostoni PVianello AOdone ADanzi GBIacoviello LBarchitta MMaresca GRavaglia CBonaccio MMinutolo FAiello LLio Vde Gaetano Donati KPatti GAntinori AMussinelli RMarcucci RVettor RBerselli ND'Ardes DPerlini SMengozzi AArboretti RMarongiu SMenichetti FMilic JBarbieri GSanrocco CVinceti MManuele RCarrozzi LParruti GCOVID-19 RISk and Treatments (CORIST) CollaborationGialluisi ACozzi OMarra LSantilli FPasi EDi Tano GColomba CRossato MVergori ACipollone FMazzitelli MGuaraldi GCastiglione GPesavento RFusco FMLarizza GCauda RSimeone PGVirano AD'Offizi GMusso MStefanini GGMeschiari MMaitan SMolena BAbete PMy ICiccullo ACrisetti AMapelli MBonfanti PCacciatore FMaccagni GMaragna ROlivieri MDi Gennaro FPivato CADe Caterina RVocciante LAgeno WSalinaro FCrosta FPalimodde AMadaro FLucia MBTrecarichi EMBartoloni APetri FBlandi LMussini CSabena AfalseRAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.<h4>Objective</h4>The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID-19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418) to retrospectively investigate the relationship between RAAS inhibitors and COVID-19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies.<h4>Methods</h4>We analyzed 4069 unselected patients with laboratory-confirmed SARS-CoV-2 infection and hospitalized in 34 clinical centers in Italy from February 19, 2020 to May 23, 2020. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin-recepto2020-01-01T00:00:00Z2020 Dec2026-05-02T17:08:20.441Z2020-10-08T07:13:14ZS-EPMC75219343299204810.1016/j.vph.2020.106805